At the end of August Jerzy Starak and Ryszard Krauze announced that they will pay zł.450 million for one third of Bioton shares and another zł.50 million after registering the new pharmaceutical. "A bear oil market and lack of success of Petrolinvest drastically limits his access to cash [Ryszard Krauze], especially in times of the financial crisis. This means that in negotiations concerning Bioton, Ryszard Krauze might have no other choice," said Paweł Burzyński.
Source: Puls Biznesu (M.M.)